LibraryMontclair State University Case LibraryScaling Psomunix: Capital, Control, and Commercialization in Biopharma

Montclair State University Case Library

To View Full Case Details.

Register Now
Already Have an account? Log In

Scaling Psomunix: Capital, Control, and Commercialization in Biopharma

Last Updated: 09/22/2026

Case Organization

Montclair State University

Affordable, inclusive, and innovative.

https://www.montclair.edu

1 Normal Avenue, Montclair, NJ 07043, United States of America

Higher Education Institution

101-500

Case Contributors

Ethne Swartz

Professor of Information Management and Entrepreneurship @ Montclair State University for 8 year(s)

Ethné Swartz, Ph.D., is Professor of Information Management and Entrepreneurship and a 2018-2019 Fulbright Scholar in South Africa where she is based at the University of Pretoria's Gordon Institute of Business Science. She joins the Feliciano School of Business from Fairleigh Dickinson’s Silberman College of Business where she was on the faculty from 2000 to 2018, holding the rank of full professor and serving as a Sam Walton Fellow and Advisor to the FDU Enactus Chapter. From 2006 to 2014, she chaired the Marketing and Entrepreneurship Department and then served as an associate dean in the Silberman College of Business. She earned a Ph.D. in in Management from the University of Manchester, Manchester, UK and an MS in Information Systems from Manchester Metropolitan University. A South African native, she holds a B.A. (Hons) in Sociology from Rhodes University, South Africa and a B.A. in Psychology/Sociology from the University of Cape Town, South Africa. Her research and teaching interests include strategic management, entrepreneurship and innovation, management of technology, business continuity and crisis management.

Dr. Swartz was a Fulbright Scholar based at Zeppelin University in Germany during the spring of 2014. She will be based at the University of Pretoria’s Gordon Institute of Business Science during spring and summer of 2019, focusing on women’s entrepreneurship in sub-Saharan Africa. She also conducts research on how women who own or manage high-growth companies can best participate in negotiating term sheets for capital investment in their companies.

Dr. Swartz is an active contributor to New Jersey’s entrepreneurial organizations and ecosystem. She has been active in the United States Association of Small Business and Entrepreneurship (USASBE), serving as a board member and as the Vice President of Conference for the annual conference in January 2011. She has served as USASBE’s Vice President of Publications, most recently creating the USASBE Annals of Entrepreneurship Education and Pedagogy, published by Edward Elgar. She is the co-author of two books and her research articles have appeared in the International Journal of Gender and Entrepreneurship, Journal of Developmental Entrepreneurship, Long Range Planning, Risk Management: An International Journal, Journal of Applied Management Studies, Leadership and Organisational Development Journal, Business Horizons, International Journal of Entrepreneurial Behaviour and Research, Facilities, Education and Training; ET&P. She serves on the editorial board of the Annals of Entrepreneurship Education and Pedagogy and previously served as an associate editor for the Journal of Small Business Management. From 1994 to October 1999, Dr. Swartz taught Strategic Management and Entrepreneurship at Leicester Business School, DeMontfort University, in Leicester, UK, where she was instrumental in setting up a center for research into business continuity management. Prior to her academic career, Dr. Swartz worked at General Motors (South Africa) and Kodak (South Africa).

Case Disciplines

Entrepreneurship Growth Strategy Legal, Regulatory, Compliance Reporting, Financial Planning & Analysis Research & Development Sales & Business Development Technology Commercialization

Skills & Expertise

Biopharmaceutical Commercialization Board-Level Communication Capitalization Strategy Cash Runway Analysis Clinical Development Strategy Competitive Benchmarking Executive Decision Making FDA Regulatory Strategy Financial Modeling Growth Strategy Implementation Roadmap Development Industry Analysis Intellectual Property Strategy Licensing Strategy Market Research Opportunity Assessment Ownership Dilution Analysis Pharmaceutical Market Analysis Resource and Capability Analysis Risk Assessment Scenario Planning Stakeholder Analysis Strategic Partnership Evaluation Technology Commercialization Valuation Analysis Venture Financing

Featured Videos

Background & Objective

The challenge or opportunity you are trying to address for the organization.

This case places you at a strategic decision point in late 2004. Psomunix LLC is an emerging biopharmaceutical company created to advance an investigational immunotherapeutic treatment for psoriasis from an unusual scientific discovery toward U.S. commercialization. What begins as a compelling medical opportunity has evolved into a much larger entrepreneurial challenge involving intellectual property, clinical development, regulatory approval, capital formation, strategic partnerships, organizational capabilities, and the competing interests of founders and investors. The opportunity originates with Dr. Flanagan, a Venezuelan immunologist and parasitologist whose work on a leishmaniasis vaccine produces an unexpected observation: some patients receiving the vaccine appear to experience substantial improvement in psoriasis symptoms. Over several years, Dr. Flanagan refines the treatment into an immunotherapeutic agent specifically intended for psoriasis and generates a substantial body of patient experience in Venezuela. One participant, Jack Goldberg, experiences a striking improvement himself and ultimately introduces the opportunity to his nephew, Mike German, and Mike's wife, Ann. Ann and Mike bring something the scientist does not: extensive pharmaceutical, financial, international, manufacturing, and operational experience. They recognize that a promising medical discovery is not automatically a viable pharmaceutical product. Commercializing the therapy in the United States requires intellectual property protection, credible clinical evidence, regulatory engagement, compliant manufacturing, experienced personnel, financing, and ultimately access to the pharmaceutical industry's commercialization infrastructure. Psomunix is therefore established in 2001 with approximately $50,000 in founder-provided seed capital. The team begins filing for U.S. patent protection, hires regulatory expertise, approaches the U.S. Food and Drug Administration, and investigates whether established pharmaceutical companies might acquire or license the opportunity. Early conversations are sobering: large pharmaceutical companies consider the asset too early-stage and want U.S.-generated clinical data before assuming the development risk.Rather than abandon the opportunity, the founders decide to build the capabilities required to advance it themselves. That decision fundamentally changes the scale of the venture. Development work must move from Venezuela to the United States. Psomunix establishes operations in New Jersey, where the founders can access pharmaceutical companies, scientific talent, regulatory expertise, investment networks, legal specialists, and other components of the region's life-sciences ecosystem. Dr. Flanagan relocates to the United States, laboratory capabilities are established, toxicology work is outsourced, and the team begins generating evidence in a form that can support the U.S. regulatory process. Capital quickly becomes one of the company's defining strategic constraints. Pharmaceutical development requires substantial investment well before a product generates commercial revenue. Psomunix' original planning estimates substantial clinical, regulatory, staffing, manufacturing, and operating requirements, with clinical development representing the largest component of anticipated future expenditures. The founders therefore need more than conventional small-business financing. They need risk capital from investors or strategic organizations willing to fund a long and uncertain development process. Through their professional and personal networks, the founders gain access to private investors and pharmaceutical industry contacts. In 2002, Psomunix successfully raises approximately $8 million through private placements despite a difficult capital environment.
Learning Objectives

This is what students will learn as they complete the case.

This case challenges students to approach biotechnology commercialization as an interconnected strategic system rather than as a single financing, scientific, or marketing decision. Students will evaluate how entrepreneurs transform an early scientific discovery into a fundable venture while balancing regulatory uncertainty, capital intensity, strategic partnerships, organizational capabilities, and founder incentives.
Students will:
  • Evaluate the attractiveness of an early-stage biotechnology opportunity using market, competitive, scientific, regulatory, and financial evidence.
  • Analyze how intellectual property, clinical evidence, management capabilities, and strategic relationships contribute to venture value.
  • Assess the regulatory and clinical-development milestones that shape risk, capital requirements, and enterprise valuation.
  • Develop and compare alternative capital strategies involving private investment, strategic pharmaceutical partnerships, licensing, and staged financing.
  • Model the relationship between capital requirements, ownership dilution, control, and future enterprise value.
  • Evaluate when an entrepreneurial biotechnology company should build capabilities internally versus partner with an established industry organization.
  • Assess competing stakeholder priorities among founders, scientists, investors, board members, strategic partners, and patients.
  • Synthesize market, regulatory, financial, organizational, and stakeholder analysis into an executive-level recommendation for both the company and its founders.
Key Action Items

These are activities and action items you might want to complete in order to achieve the expected outcomes.

Milestones
Milestone #1
Guiding Questions
Deliverable
Suggested Outcome(s)
Milestone #2
Guiding Questions
Deliverable
Suggested Outcome(s)
Milestone #3
Guiding Questions
Deliverable
Suggested Outcome(s)
Milestone #4
Guiding Questions
Deliverable
Suggested Outcome(s)
Milestone #5
Guiding Questions
Deliverable
Suggested Outcome(s)

Explore the CapSource Case Library

Explore Case Library

The CapSource Case Library helps students explore real-world challenges faced by leading organizations across industries. Each case introduces a practical business or social impact problem and invites students to think critically about potential solutions.

Students can use cases to:

Discover potential career paths and industries
Learn how organizations approach strategy, operations, and innovation
Practice solving real-world challenges
Build a portfolio of real work product that showcase impact

Educators can register and browse the library for free. Upgrade for classroom use to bring experiential learning into your courses through case discussions, assignments, and competitions. The library is constantly growing and used by schools everywhere.

What you get when you upgrade:

Case notes and discussion/facilitation guides
In class presentation slides and teaching support materials
Visibility of student submissions and industry feedback
Evaluation tools and outcomes reporting

Unlock the Full Case

Create a free account to browse case materials, submit custom cases/case responses, and explore ways you can leverage this material to improve classroom engagement and enhance learning outcomes.

Register to View Full Case Details

Register Now

Already have an account? Log In

Educator or organization? Book A Demo